哥伦比亚波哥大2008-2019年多中心研究:PCV10引入前后培养确诊儿童肺炎球菌肺炎的流行病学特征与血清型分布
该多中心研究纳入波哥大10家医院2008-2019年370例培养确诊的儿童肺炎球菌肺炎病例,比较PCV10接种前(2008-2011年)与接种后(2014-2019年)的流行病学和临床特征,发现PCV10显著减少血清型1和14病例,但血清型19A、3和6A病例增加,且复杂性肺炎、住院时间、PICU入住率和广谱抗生素使用均增加。
要点
- PCV10接种后血清型1和14病例减少,血清型19A、3和6A病例增加(p < 0.001)。
- 复杂性肺炎从13.4%增至31.8%(p < 0.001),PICU入住率从32.8%增至51.6%(p = 0.001)。
- 住院时间从8(5.5-15)天延长至12(7-22)天(p < 0.001),经验性抗生素疗程从7(4-11)天延长至10(6-17)天(p < 0.001)。
核心结论
- PCV10显著减少血清型1和14病例,但血清型19A、3和6A成为优势血清型且病情更重(如PICU入住、复杂性肺炎和更多耐药),这些血清型随后被纳入PCV13。
- 当前数据支持国家和区域证据,即用包含19A的更高价疫苗(如PCV13)替代PCV10,以减少特别是该血清型的传播。
研究设计与样本
- 多中心研究,纳入波哥大10家医院2008-2019年培养确诊的肺炎球菌肺炎病例,比较PCV10接种前(2008-2011年)与接种后(2014-2019年)两个时期。
主要发现
- 共纳入370例病例。
- PCV10前血清型1(15例,11.2%)和14(33例,24.6%)最常见,血清型19A仅4例(3%),血清型3仅1例(0.7%)。
- 从PCV10前到PCV10后,血清型1病例(6例,3.1%)和14病例(1例,7.8%)减少,而血清型19A(58例,30.2%)、血清型3(32例,16.7%)和6A(7例,3.6%)病例增加(p < 0.001)。
- 复杂性肺炎显著增加(13.4%至31.8%)(p < 0.001);住院时间从8(5.5-15)天延长至12(7-22)天(p < 0.001);PICU入住率从32.8%增至51.6%(p = 0.001)。
- PCV10后氨苄西林-舒巴坦使用率(0.7%至24%)和头孢曲松/克林霉素使用率(0.7%至5.7%)增加;经验性抗生素疗程从7(4-11)天延长至10(6-17)天(p < 0.001);病死率略有非显著增加(7.5% vs. 9.9%;p = 0.57)。
临床怎么用
- 作者认为当前数据支持国家和区域证据,即用包含19A的更高价疫苗(如PCV13)替代PCV10,以减少特别是该血清型的传播。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pneumococcal conjugate vaccines (PCVs) have decreased pneumonia in children. Colombia introduced mass vaccination with PCV10 in 2012. METHODS: Cases of pneumococcal pneumonia from 10 hospitals were included. Two periods were compared: pre-PCV10: 2008-2011 and post-PCV10: 2014-2019. The objective was to compare epidemiological and clinical characteristics before and after PCV10 vaccination. RESULTS: A total of 370 cases were included. Serotypes 1 (15, 11.2%) and 14 (33, 24.6%) were the most frequent in the pre-PCV10 period, with only 4 (3%) cases of serotype 19A and 1 case (0.7%) serotype 3. From the pre-PCV10 period to the post-PCV10 period, cases of serotypes 1 (6, 3.1%) and 14 (1, 7.8%) decreased, while cases of serotypes 19A (58, 30.2%), serotype 3 (32, 16.7%) and 6A (7, 3.6%) increased (p < 0.001); complicated pneumonia (CP) increased significantly (13.4% to 31.8%) (p < 0.001); hospitalizations increased from 8 (5.5-15) to 12 (7-22) days (p < 0.001); and the frequency of PICU admission increased from 32.8% to 51.6% (p = 0.001). The use of ampicillin-sulbactam (0.7% to 24%) and ceftriaxone/clindamycin (0.7% to 5.7%) increased in the post-PCV10 period. The duration of empirical antibiotic treatment was 7 (4-11) days in the pre-PCV10 period and increased to 10 (6-17) days (p < 0.001) in the post-PCV10 period. Lethality showed a slight nonsignificant increase (7.5% vs. 9.9%; p = 0.57) in the post-PCV10 period. CONCLUSIONS: PCV10 significantly decreased cases of serotypes 1 and 14, with an increase in cases of serotypes 19A, 3 and 6A, which were the predominant serotypes and had greater severity (e.g., admission to the PICU, CP and more resistance, with an increase in the use of broad-spectrum antibiotics and longer hospitalization) and subsequently included in PCV13. Current data support national and regional evidence on the importance of replacing PCV10 with a higher valence that includes 19A, such as PCV13, with the aim of reducing circulation, particularly of this serotype.
引用
- Gutiérrez-Tobar IF, Londoño-Ruiz JP, Mariño-Drews C, et al. Epidemiological characteristics and serotype distribution of culture-confirmed pediatric pneumococcal pneumonia before and after PCV 10 introduction, a multicenter study in Bogota, Colombia, 2008-2019. Vaccine. 2022. PMID: 35396166. doi:10.1016/j.vaccine.2022.03.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。